The Roundtable Versus The Banquet Table
This article was originally published in RPM Report
There will be extensive jockeying for attention over the next year from House Energy & Commerce Chairman Fred Upton for the “3D’s” review of drug legislation. NORD was not at the kick-off Capitol Hill roundtable but may already have the chairman’s ear -- or at least his emotional backing.
You may also be interested in...
The Energy & Commerce Committee “21st Century Cures” Process promises to set a pro-innovation tone heading into the next user fee reauthorization cycle. There is one theme, however, that may be perilous for industry moving forward: Expanded Access.
FDA is joining the government’s bioresponse and defense efforts to develop small, mobile, on-demand manufacturing systems as next-tech solutions to dwindling domestic supply sources for essential drugs.
How should FDA make sure new safety information gets widely disseminated – especially against a history of many communications that have not shown the sustained ability to reach the most active prescribers? The agency got an earful of suggestions from the most recent safety review of the asthma/allergy drug montelukast.